Src_NP Kinase_NP becomes_VBZ preferentially_RB associated_VBN with_IN the_DT VEGFR_NP ,_, KDR/Flk-1_NP ,_, following_VBG VEGF_NP stimulation_NN of_IN vascular_JJ endothelial_JJ cells_NNS Abstract_NP |_SYM Background_NN |_SYM The_DT cytoplasmic_JJ tyrosine_NN kinase_NN ,_, Src_NP ,_, has_VBZ been_VBN found_VBN to_TO play_VB a_DT crucial_JJ role_NN in_IN VEGF_NP (_( vascular_JJ endothelial_JJ growth_NN factor_NN )_) --_: dependent_JJ vascular_JJ permeability_NN involved_VBN in_IN angiogenesis_NN ._SENT The_DT two_CD main_JJ VEGFRs_NNS present_JJ on_IN vascular_JJ endothelial_JJ cells_NNS are_VBP KDR/Flk-1_NP (_( kinase_NN insert_NN domain-containing_VBG receptor/fetal_JJ liver_NN kinase-1_NN )_) and_CC Flt-1_NP (_( Fms-like_JJ tyrosine_NN kinase-1_NN )_) ._SENT However_RB ,_, to_TO date_VB ,_, it_PP has_VBZ not_RB been_VBN determined_VBN which_WDT VEGF_NP receptor_NN (_( VEGFR_NP )_) is_VBZ involved_VBN in_IN binding_VBG to_TO and_CC activating_VBG Src_NP kinase_NN following_VBG VEGF_NP stimulation_NN of_IN the_DT receptors_NNS ._SENT Results_NNS |_SYM In_IN this_DT report_NN ,_, we_PP demonstrate_VBP that_IN Src_NP preferentially_RB associates_NNS with_IN KDR/Flk-1_NP rather_RB than_IN Flt-1_NP in_IN human_JJ umbilical_JJ vein_NN endothelial_JJ cells_NNS (_( HUVECs_NP )_) ,_, and_CC that_DT VEGF_NP stimulation_NN resulted_VBD in_IN an_DT increase_NN of_IN Src_NP activity_NN associated_VBN with_IN activated_VBN KDR/Flk-1_NP ._SENT These_DT findings_NNS were_VBD determined_VBN through_IN immunoprecipitation-kinase_NN experiments_NNS and_CC coimmunoprecipitation_NN studies_NNS ,_, and_CC were_VBD further_RBR confirmed_VBN by_IN GST-pull-down_NP assays_NNS and_CC Far_JJ Western_JJ studies_NNS ._SENT However_RB ,_, Fyn_NP and_CC Yes_NP ,_, unlike_IN Src_NP ,_, were_VBD found_VBN to_TO associate_VB preferentially_RB with_IN Flt-1_NP ._SENT Conclusions_NNS |_SYM Thus_RB ,_, Src_NP preferentially_RB associates_NNS with_IN KDR/Flk-1_NP ,_, rather_RB than_IN with_IN Flt-1_NP ,_, upon_IN VEGF_NP stimulation_NN in_IN endothelial_JJ cells_NNS ._SENT Our_PP$ findings_NNS further_RBR highlight_VB the_DT potential_JJ significance_NN of_IN upregulated_JJ KDR/Flk-1-associated_NP Src_NP activity_NN in_IN the_DT process_NN of_IN angiogenesis_NN ,_, and_CC help_VB to_TO elucidate_VB more_RBR clearly_RB the_DT specific_JJ roles_NNS and_CC mechanisms_NNS involving_VBG Src_NP family_NN tyrosine_NN kinase_NN in_IN VEGF-stimulated_JJ signal_NN transduction_NN events_NNS ._SENT Angiogenesis_NP is_VBZ a_DT process_NN that_WDT is_VBZ of_IN critical_JJ importance_NN to_TO tumorigenesis_NN and_CC tumor_NN metastasis_NN ,_, as_RB well_RB as_IN to_TO the_DT growth_NN and_CC maintenance_NN of_IN normal_JJ vasculature_NN ._SENT Both_CC the_DT processes_NNS of_IN angiogenesis_NN and_CC tumorigenic_JJ proliferation_NN are_VBP key_JJ events_NNS essential_JJ for_IN the_DT successful_JJ growth_NN of_IN vascularized_JJ tumors_NNS ._SENT Indeed_RB ,_, inhibition_NN of_IN neovascularization_NN has_VBZ been_VBN shown_VBN to_TO abolish_VB or_CC slow_VB tumor_NN growth_NN in_IN various_JJ experimental_JJ models_NNS ._SENT Angiogenesis_NP plays_VBZ both_DT beneficial_JJ and_CC detrimental_JJ roles_NNS in_IN normal_JJ and_CC disease_NN processes_NNS ._SENT For_IN example_NN ,_, abnormally_RB enhanced_VBN angiogenic_JJ responses_NNS are_VBP observed_VBN during_IN conditions_NNS such_JJ as_IN diabetic_JJ retinopathy_NN and_CC rheumatoid_JJ arthritis_NN ._SENT On_IN the_DT other_JJ hand_NN ,_, promotion_NN of_IN the_DT angiogenic_JJ response_NN has_VBZ been_VBN demonstrated_VBN to_TO be_VB beneficial_JJ in_IN treating_VBG ischemic_JJ conditions_NNS ,_, such_JJ as_IN myocardial_JJ ischemia/infarction_NN ._SENT Thus_RB ,_, a_DT comprehensive_JJ understanding_NN of_IN the_DT molecular_JJ mechanisms_NNS underlying_VBG the_DT angiogenic_JJ response_NN may_MD help_VB in_IN preventing_VBG and_CC treating_VBG many_JJ diseases_NNS displaying_VBG aberrant_JJ angiogenesis_NN ._SENT VEGF_NP is_VBZ an_DT angiogenic_JJ factor_NN that_WDT is_VBZ very_RB closely_RB associated_VBN with_IN the_DT induction_NN and_CC maintenance_NN of_IN neovasculature_NN in_IN human_JJ cancers_NNS ._SENT Although_IN other_JJ splice_NN variant_NN forms_NNS of_IN VEGF_NP have_VBP been_VBN discovered_VBN to_TO be_VB encoded_VBN and_CC expressed_VBN ,_, VEGF-A165_NP remains_VBZ the_DT main_JJ biologically_RB relevant_JJ splice_NN form_NN ._SENT VEGF-A165_NP is_VBZ produced_VBN from_IN tumor_NN cells_NNS and_CC stromal_JJ fibroblast_NN cells_NNS ,_, and_CC is_VBZ able_JJ to_TO bind_VB both_DT KDR/Flk-1_NP and_CC Flt-1_NP (_( two_CD main_JJ VEGF_NP receptors_NNS of_IN the_DT VEGF_NP family_NN expressed_VBD by_IN vascular_JJ endothelial_JJ cells_NNS )_) ._SENT VEGF-A165_NP exhibits_VBZ two_CD major_JJ biological_JJ activities_NNS ._SENT One_CD ,_, is_VBZ that_IN it_PP promotes_VBZ increased_VBN microvascular_JJ hyperpermeability_NN to_TO circulating_VBG plasma_NN proteins_NNS (_( one_CD of_IN the_DT steps_NNS important_JJ in_IN early_JJ vasculogenesis_NN )_) ._SENT This_DT leads_VBZ to_TO extravasation_NN of_IN fibrinogen_NN and_CC other_JJ plasma_NN proteins_NNS ,_, activation_NN of_IN the_DT clotting_VBG system_NN ,_, and_CC deposition_NN of_IN a_DT fibrin_NN gel_NN in_IN the_DT extravascular_JJ space_NN ._SENT The_DT fibrin_NN gel_NN provides_VBZ a_DT proangiogenic_JJ matrix_NN that_WDT favors_VBZ and_CC supports_VBZ the_DT migration_NN of_IN fibroblasts_NNS and_CC the_DT growth_NN of_IN new_JJ blood_NN vessels_NNS ._SENT Another_DT major_JJ biological_JJ activity_NN of_IN VEGF-A165_NP is_VBZ its_PP$ ability_NN to_TO stimulate_VB vascular_JJ endothelial_JJ cell_NN proliferation_NN ._SENT The_DT VEGF_NP receptors_NNS ,_, KDR/Flk-1_NP and_CC Flt-1_NP ,_, are_VBP receptor_NN tyrosine_NN kinases_NNS structurally_RB related_VBN to_TO receptors_NNS of_IN the_DT Fms/Kit/PDGFR_NP family_NN ._SENT Both_DT VEGFRs_NNS contain_VBP a_DT large_JJ insert_NN sequence_NN in_IN their_PP$ respective_JJ intracellular_JJ kinase_NN domains_NNS and_CC seven_CD immunoglobulin-like_JJ domains_NNS in_IN their_PP$ respective_JJ NH2-terminal_JJ regions_NNS ._SENT Also_RB ,_, both_DT KDR/Flk-1_NP and_CC Flt-1_NP have_VBP been_VBN shown_VBN to_TO be_VB expressed_VBN mainly_RB on_IN endothelial_JJ cells_NNS ,_, and_CC to_TO play_VB important_JJ roles_NNS in_IN transducing_VBG signals_NNS upon_IN VEGF_NP stimulation_NN of_IN the_DT endothelium_NN ._SENT Previous_JJ knockout_NN studies_NNS have_VBP demonstrated_VBN that_IN KDR/Flk-1_NP (_( -/-_NN )_) mice_NNS exhibit_VBP embryonic_JJ lethality_NN (_( at_IN E8.5-E9.0_NP )_) ._SENT They_PP exhibit_VBP no_DT development_NN of_IN blood_NN vessels_NNS and_CC very_RB low_JJ hematopoiesis_NNS ._SENT Flt-1_NP (_( -/-_NN )_) mice_NNS also_RB exhibit_VBP embryonic_JJ lethality_NN (_( at_IN E8.5_NP )_) ,_, but_CC as_IN a_DT result_NN of_IN overgrowth_NN of_IN endothelial_JJ cells_NNS and_CC disorganization_NN of_IN blood_NN vessels_NNS ._SENT This_DT suggests_VBZ that_IN at_IN least_JJS in_IN the_DT early_JJ stages_NNS of_IN embryogenesis_NN ,_, KDR/Flk-1_NP is_VBZ essential_JJ for_IN both_DT proliferation_NN and_CC differentiation_NN of_IN endothelial_JJ cells_NNS ,_, whereas_IN Flt-1_NP can_MD potentially_RB act_VB as_IN a_DT negative_JJ regulator_NN of_IN cell_NN proliferation_NN in_IN the_DT assembly_NN of_IN the_DT vascular_JJ endothelium_NN ._SENT These_DT and_CC other_JJ observations_NNS indicate_VBP that_IN KDR/Flk-1_NP and_CC Flt-1_NP may_MD have_VB different_JJ biological_JJ functions_NNS ,_, and_CC suggest_VBP that_IN they_PP may_MD utilize_VB different_JJ downstream_IN signaling_VBG pathways_NNS ._SENT Src_NP is_VBZ a_DT cytoplasmic_JJ protein_NN tyrosine_NN kinase_NN ,_, whose_WP$ activation_NN and_CC recruitment_NN to_TO perimembranal_JJ signaling_VBG complexes_NNS has_VBZ important_JJ implications_NNS for_IN cellular_JJ fate_NN ._SENT It_PP has_VBZ well-documented_VBN that_DT Src_NP protein_NN levels_NNS and_CC Src_NP kinase_NN activity_NN are_VBP significantly_RB elevated_VBN in_IN human_JJ breast_NN cancers_NNS ,_, colon_NN cancers_NNS ,_, and_CC pancreatic_JJ cancers_NNS as_IN well_RB ._SENT Furthermore_RB ,_, activation_NN of_IN Src_NP by_IN growth_NN factors_NNS and_CC growth_NN factor_NN receptors_NNS ,_, such_JJ as_IN PDGF(R)_NP ,_, EGF(R)_NP ,_, and_CC HER2/Neu_NP ,_, has_VBZ been_VBN shown_VBN to_TO promote_VB cell_NN proliferation_NN ._SENT The_DT biological_JJ importance_NN of_IN Src_NP in_IN the_DT VEGF_NP angiogenic_JJ system_NN was_VBD published_VBN in_IN a_DT report_NN by_IN Eliceiri_NP and_CC collaborators_NNS ._SENT Their_PP$ experiments_NNS used_VBD a_DT CAM_NP model_NN (_( chick_NN embryo_NN chorioallantoic_JJ membrane_NN model_NN )_) and_CC a_DT murine_JJ subcutaneous_JJ angiogenesis_NN model_NN to_TO demonstrate_VB a_DT crucial_JJ role_NN for_IN Src_NP in_IN VEGF-dependent_NP vascular_JJ permeability_NN ._SENT Also_RB ,_, Suarez_NP and_CC Ballmer-Hofer_NP proposed_VBD from_IN their_PP$ study_NN that_IN VEGF-mediated_JJ disruption_NN of_IN gap_NN junctional_JJ communication_NN in_IN endothelial_JJ cells_NNS via_IN Src_NP was_VBD the_DT cause_NN of_IN local_JJ increased_VBN endothelial_JJ permeability_NN ._SENT To_TO date_NN ,_, it_PP has_VBZ been_VBN assumed_VBN that_IN Src_NP becomes_VBZ activated_VBN in_IN endothelial_JJ cells_NNS following_VBG binding_JJ to_TO an_DT activated_VBN VEGF_NP receptor_NN ._SENT However_RB ,_, it_PP is_VBZ not_RB known_VBN whether_IN Src_NP binds_NNS and_CC is_VBZ activated_VBN by_IN one_CD VEGFR_NP or_CC is_VBZ able_JJ to_TO bind_VB and_CC be_VB activated_VBN by_IN both_DT VEGFRs_NN to_TO a_DT substantial_JJ degree_NN ._SENT Our_PP$ study_NN reveals_VBZ that_IN Src_NP preferentially_RB associates_NNS with_IN and_CC is_VBZ subsequently_RB activated_VBN by_IN KDR/Flk-1_NP rather_RB than_IN with_IN Flt-1_NP in_IN HUVECs_NP (_( human_JJ umbilical_JJ vein_NN endothelial_JJ cells_NNS )_) ._SENT Coimmunoprecipitation_NN of_IN Src_NP activity_NN with_IN KDR/Flk-1_NP |_SYM A_DT potentially_RB important_JJ biological_JJ role_NN for_IN Src_NP in_IN VEGF-dependent_NP vascular_JJ permeability_NN has_VBZ been_VBN previously_RB reported_VBN ._SENT However_RB ,_, it_PP is_VBZ not_RB known_VBN if_IN one_CD or_CC both_DT of_IN the_DT main_JJ endothelial_JJ VEGF_NP receptors_NNS (_( VEGFRs_NP )_) are_VBP specifically_RB able_JJ to_TO bind_VB to_TO and_CC activate_VB Src_NP ._SENT We_PP compared_VBD the_DT ability_NN of_IN the_DT two_CD main_JJ types_NNS of_IN endothelial_JJ VEGFRs_NNS (_( KDR/Flk-1_NP and_CC Flt-1_NP )_) to_TO associate_VB with_IN and_CC activate_VB Src_NP upon_IN VEGF_NP treatment_NN ,_, by_IN determining_VBG whether_IN Src_NP activity_NN could_MD be_VB coimmunoprecipitated_VBN with_IN either_DT receptor_NN ._SENT HUVECs_NNS were_VBD either_RB serum-starved_VBN ,_, or_CC serum-starved_JJ and_CC then_RB treated_VBN with_IN VEGF_NP ,_, or_CC lysed_VBN (_( unstarved_JJ ,_, untreated_JJ )_) at_IN subconfluence_NN ._SENT Cell_NN extracts_VBZ of_IN these_DT samples_NNS were_VBD then_RB immunoprecipitated_JJ using_VBG alpha-KDR/Flk-1_NN (_( N-931_NP )_) ,_, alpha-Flt-1_JJ (_( H-225_NP )_) ,_, or_CC nonimmune_NN rabbit_NN IgG_NP ;_: and_CC kinase_NN assays_NNS were_VBD performed_VBN using_VBG these_DT immunocomplexes_NNS ._SENT Upon_IN VEGF_NP treatment_NN ,_, both_CC KDR/Flk-1_NP and_CC Flt-1_NP become_VBP tyrosine-phosphorylated_JJ ._SENT This_DT is_VBZ accompanied_VBN by_IN a_DT 2.15-fold_JJ increase_NN in_IN phosphorylation_NN of_IN a_DT 60_CD kDa_NN protein_NN (_( corresponding_JJ to_TO the_DT molecular_JJ weight_NN of_IN Src_NP )_) associated_VBN with_IN KDR/Flk-1_NP and_CC a_DT 1.71-fold_NN increase_NN in_IN enolase_NN substrate_NN phosphorylation_NN activity_NN associated_VBN with_IN the_DT KDR/Flk-1_NP immunocomplexes_NNS ._SENT However_RB ,_, there_EX was_VBD very_RB little_JJ detectable_JJ p60_NN kDa_NN phosphorylation_NN or_CC enolase_NN substrate_NN phosphorylation_NN activity_NN associated_VBN with_IN the_DT Flt-1_JJ immunocomplexes_NNS ._SENT Yet_RB ,_, Flt-1_NP was_VBD found_VBN to_TO be_VB immunoprecipitatable_JJ and_CC tyrosine-phosphorylated_JJ upon_IN VEGF_NP treatment_NN (_( Fig._NN ,_, left_VBN panel_NN )_) ._SENT Also_RB ,_, nonimmune_JJ rabbit_NN IgG_NP did_VBD not_RB coprecipitate_VB any_DT significant_JJ levels_NNS of_IN p60_JJ kDa_NN phosphorylation_NN or_CC enolase_NN substrate_NN phosphorylation_NN ._SENT Kinase_NN reactions_NNS were_VBD also_RB performed_VBN on_IN Src_NP optimal_JJ peptide_NN substrate_NN (_( AEEEIYGEFEAKKKK_NP )_) with_IN similar_JJ results_NNS (_( unpublished_JJ observations_NNS )_) ._SENT Figure_NP 1_CD |_SYM Src_NP Activity_NP coprecipitates_VBZ with_IN KDR/Flk-1_NP Src_NP Activity_NN coprecipitates_NNS with_IN KDR/Flk-1_NP ._SENT (_( A_NP )_) HUVECs_NP were_VBD either_RB serum-starved_JJ (_( -_: )_) ,_, or_CC starved_VBN and_CC then_RB VEGF-treated_JJ (_( 15_CD ng/mL_NNS VEGF_NP for_IN 15_CD min_NN ._SENT )_) (_( +_SYM )_) ,_, or_CC lysed_VBN (_( unstarved_JJ ,_, untreated_JJ )_) at_IN subconfluence_NN (_( C_NP )_) ._SENT Cell_NN extracts_VBZ of_IN these_DT samples_NNS were_VBD immunoprecipitated_JJ using_VBG alpha-Flt-1_NN (_( H-225_NP )_) ,_, alpha-KDR/Flk-1_JJ (_( N-931_NP )_) ,_, or_CC rabbit_NN nonimmune_NN IgG_NP ._SENT Kinase_NN assay_NN reactions_NNS were_VBD subsequently_RB performed_VBN using_VBG enolase_NN substrate_NN ._SENT Samples_NNS were_VBD resolved_VBN on_IN 10_CD %_NN SDS-PAGE_NN gels_NNS ._SENT The_DT gels_NNS were_VBD treated_VBN with_IN 1_CD M_NP KOH_NP at_IN 55C_NP for_IN 1_CD h_NN after_IN electrophoresis_NN to_TO remove_VB background_NN due_JJ to_TO serine_NN phosphorylation_NN ._SENT The_DT gels_NNS were_VBD then_RB dried_VBN and_CC exposed_VBN to_TO autoradiographic_NN film_NN (_( upper_JJ panel_NN )_) ._SENT (_( B_NP )_) Cell_NP extracts_VBZ from_IN the_DT indicated_JJ treatment_NN conditions_NNS were_VBD immunoprecipitated_JJ using_VBG alpha-Flt-1_NN (_( H-225_NP )_) and_CC immunoblotted_JJ using_VBG alpha-phosphotyrosine_NN (_( 4G10_JJ )_) or_CC alpha-Flt-1_JJ (_( H-225_NP )_) (_( left_JJ panel_NN )_) ;_: or_CC the_DT cell_NN extracts_VBZ were_VBD immunoprecipitated_VBN using_VBG alpha-KDR/Flk-1_JJ (_( A-3_NP )_) and_CC immunoblotted_JJ using_VBG alpha-phosphotyrosine_NN (_( 4G10_JJ )_) or_CC alpha-KDR/Flk-1_JJ (_( N-931_NP )_) (_( right_JJ panel_NN )_) ._SENT Time-dependent_JJ VEGF_NP stimulation_NN of_IN Src_NP association_NN with_IN KDR/Flk-1_NP |_SYM In_IN order_NN to_TO further_RBR study_VB the_DT specificity_NN and_CC time-course_NN of_IN Src_NP association_NN with_IN KDR/Flk-1_NP ,_, HUVECs_NP (_( human_JJ umbilical_JJ vein_NN endothelial_JJ cells_NNS )_) were_VBD serum-starved_VBN and_CC then_RB treated_VBN with_IN VEGF_NP (_( 15_CD ng/mL_NNS )_) for_IN 0_CD ,_, 15_CD ,_, 30_CD ,_, 60_CD ,_, or_CC 120_CD min_NN ._SENT As_IN seen_VBN in_IN Figure_NP ,_, Src_NP association_NN with_IN KDR/Flk-1_NP peaked_VBD around_RP 15_CD min_NN of_IN VEGF_NP treatment_NN ._SENT Concurrently_RB ,_, KDR/Flk-1_NP phosphorylation_NN initially_RB increased_VBN and_CC then_RB decreased_VBD ,_, peaking_VBG at_IN about_RB 15_CD minutes_NNS ._SENT Our_PP$ results_NNS also_RB indicate_VBP that_IN the_DT association_NN of_IN activated_VBN Src_NP phosphorylated_JJ on_IN tyrosine_NN 419_CD with_IN KDR/Flk-1_NP peaked_VBD at_IN approximately_RB 15_CD minutes_NNS of_IN VEGF_NP treatment_NN ._SENT This_DT was_VBD detected_VBN by_IN alpha-Src_NN phosphotyrosine_NN 419_CD specific_JJ Src_NP antibody_NN that_WDT is_VBZ able_JJ to_TO detect_VB an_DT activated_VBN form_NN of_IN c-Src_NP ._SENT Because_IN of_IN logistical_JJ considerations_NNS ,_, we_PP did_VBD not_RB examine_VB time_NN points_NNS between_IN 0_CD and_CC 15_CD minutes_NNS ._SENT Therefore_RB ,_, we_PP cannot_MD exclude_VB the_DT possibility_NN that_IN a_DT substantial_JJ level_NN of_IN activation_NN of_IN KDR/Flk-1_NP and_CC Src_NP did_VBD not_RB also_RB occur_VB at_IN these_DT earlier_JJR times_NNS ._SENT We_PP also_RB studied_VBD the_DT time_NN course_NN of_IN Src_NP association_NN with_IN Flt-1_NP ._SENT However_RB ,_, we_PP did_VBD not_RB find_VB detectable_JJ Src_NP association_NN with_IN Flt-1_NP up_RB to_TO 120_CD minutes_NNS after_IN VEGF_NP treatment_NN ._SENT At_IN the_DT same_JJ time_NN it_PP was_VBD evident_JJ that_IN Flt-1_NP was_VBD phosphorylated_JJ upon_IN VEGF_NP treatment_NN ._SENT These_DT results_NNS suggested_VBD to_TO us_PP that_IN Src_NP preferentially_RB associated_VBN with_IN KDR/Flk-1_NP rather_RB than_IN Flt-1_NP upon_IN VEGF_NP treatment_NN ._SENT Figure_NP 2_CD |_SYM Time-dependent_NP VEGF_NP stimulation_NN of_IN Src_NP association_NN with_IN KDR/Flk-1_NP Time-dependent_NP VEGF_NP stimulation_NN of_IN Src_NP association_NN with_IN KDR/Flk-1_NP ._SENT HUVECs_NNS were_VBD serum-starved_JJ and_CC then_RB treated_VBN with_IN VEGF_NP (_( 15_CD ng/mL_NNS )_) for_IN 0_CD ,_, 15_CD ,_, 30_CD ,_, 60_CD ,_, or_CC 120_CD min_NN ._SENT (_( A_NP )_) Cell_NP extracts_VBZ from_IN the_DT indicated_JJ treatment_NN conditions_NNS were_VBD immunoprecipitated_JJ using_VBG alpha-Src_NN 2_CD --_: 17_CD ,_, and_CC immunoblotted_JJ using_VBG alpha-KDR/Flk-1_NN (_( N-931_NP )_) or_CC alpha-Src_NP 327_CD ._SENT (_( B_NP )_) Cell_NP extracts_VBZ from_IN the_DT indicated_JJ treatment_NN conditions_NNS were_VBD immunoprecipitated_JJ using_VBG alpha-KDR/Flk-1_NN (_( N-931_NP )_) ,_, and_CC immunoblotted_JJ using_VBG alpha-phosphotyrosine_NN (_( 4G10_JJ )_) ,_, alpha-phosphotyrosine_NN 419_CD Src_NP ,_, or_CC alpha-KDR/Flk-1_JJ (_( A-3_NP )_) ._SENT (_( C_NP )_) Cell_NP extracts_VBZ from_IN the_DT indicated_JJ treatment_NN conditions_NNS were_VBD immunoprecipitated_JJ using_VBG alpha-Src_NN 2_CD --_: 17_CD ,_, and_CC immunoblotted_JJ using_VBG alpha-Flt-1_NN (_( H-225_NP )_) or_CC alpha-Src_NP 327_CD ._SENT (_( D_NP )_) Cell_NP extracts_VBZ from_IN the_DT indicated_JJ treatment_NN conditions_NNS were_VBD immunoprecipitated_JJ using_VBG alpha-Flt-1_NN (_( H-225_NP )_) ,_, and_CC immunoblotted_JJ using_VBG alpha-phosphotyrosine_NN (_( 4G10_JJ )_) ,_, alpha-Src_NP 327_CD ,_, or_CC alpha-Flt-1_JJ (_( H-225_NP )_) ._SENT Src_NP SH3-SH2_NP association_NN with_IN KDR/Flk-1_NP increases_NNS upon_IN VEGF_NP stimulation_NN |_SYM In_IN order_NN to_TO confirm_VB Src_NP preference_NN for_IN interaction_NN with_IN Flk-1/KDR_NP compared_VBN to_TO Flt-1_NP ,_, we_PP tested_VBD GST-Src_NP domain_NN fusion_NN constructs_NNS for_IN their_PP$ ability_NN to_TO bind_VB to_TO KDR/Flk-1_NP in_IN GST-pull-down_NP experiments_NNS ._SENT The_DT results_NNS indicated_VBD that_IN VEGF-stimulated_NP KDR/Flk-1_NP was_VBD able_JJ to_TO bind_VB strongly_RB to_TO constructs_NNS containing_VBG both_CC the_DT Src_NP SH3_NP and_CC SH2_NP domains_NNS ._SENT Some_DT basal_JJ binding_NN of_IN KDR/Flk-1_NP to_TO the_DT Src_NP SH3-SH2_NP and_CC Src_NP U-SH3-SH2_NP was_VBD observed_VBN ,_, although_IN the_DT extent_NN of_IN this_DT binding_NN was_VBD less_JJR than_IN the_DT binding_NN observed_VBD after_IN VEGF_NP treatment_NN ._SENT The_DT Src_NP unique_JJ domain_NN alone_RB was_VBD not_RB able_JJ to_TO bind_VB to_TO KDR/Flk-1_NP ,_, but_CC it_PP seemed_VBD to_TO augment_VB binding_JJ when_WRB present_JJ in_IN a_DT construct_NN containing_VBG both_CC the_DT Src_NP SH3_NP and_CC SH2_NP domains_NNS ._SENT Notably_RB ,_, however_RB ,_, upon_IN VEGF_NP stimulation_NN and_CC tyrosine_NN phosphorylation_NN of_IN KDR/Flk-1_NP ,_, the_DT ability_NN of_IN KDR/Flk-1_NP to_TO bind_VB to_TO Src_NP SH3-SH2_NP was_VBD increased_VBN ._SENT Figure_NP 3_CD |_SYM GST_JJ pull-downs_NNS and_CC Far_JJ Western_JJ blots_NNS indicate_VBP increased_VBN Src_NP SH3-SH2_NP interaction_NN with_IN KDR/Flk-1_NP upon_IN VEGF_NP stimulation_NN GST_JJ pull-downs_NNS and_CC Far_JJ Western_JJ blots_NNS indicate_VBP increased_VBN Src_NP SH3-SH2_NP interaction_NN with_IN KDR/Flk-1_NP upon_IN VEGF_NP stimulation_NN ._SENT (_( A_NP )_) HUVECs_NP were_VBD either_RB serum-starved_JJ (_( 0_CD '_'' )_) or_CC starved_VBN and_CC then_RB VEGF-treated_JJ (_( 15_CD ng/mL_NNS for_IN 15_CD min_NN )_) (_( 15_CD '_'' )_) ._SENT The_DT indicated_JJ GST-Src_NP domain_NN fusion_NN proteins_NNS (_( see_VB below_IN )_) bound_VBN to_TO glutathione-agarose_JJ beads_NNS were_VBD used_VBN (_( 500_CD pmol_NN equimolar_NN amounts_VBZ each_DT )_) ,_, in_IN pull-down_JJ incubations_NNS with_IN equal_JJ amounts_NNS of_IN protein_NN lysate_NN samples_NNS (_( 500_CD mug_NN each_DT )_) ._SENT The_DT pull-down_JJ complexes_NNS were_VBD resolved_VBN on_IN a_DT 7_CD %_NN acrylamide_NN SDS-PAGE_NP gel_NN and_CC transferred_VBN to_TO nitrocellulose_NN ._SENT Immunoblotting_NN was_VBD then_RB performed_VBN using_VBG alpha-KDR/Flk-1_JJ (_( A-3_NP )_) or_CC alpha-Flt-1_JJ (_( H-225_NP )_) ._SENT GU_NP ,_, GST-Src_NP unique_JJ domain_NN fusion_NN protein_NN ;_: GU32_NP ,_, GST-Src_NP unique_JJ SH3_NP SH2_NP domain_NN fusion_NN protein_NN ;_: G32_NP ,_, GST-Src_NP SH3_NP SH2_NP domain_NN fusion_NN protein_NN ._SENT (_( B_LS )_) Cell_JJ extract_NN (_( pre-pull-down_NN )_) input_NN levels_NNS of_IN phosphotyrosine_JJ KDR/Flk-1_NP and_CC KDR/Flk-1_NP ,_, from_IN HUVECs_NP either_CC serum-starved_JJ (_( 0_CD '_'' )_) or_CC starved_VBN and_CC then_RB VEGF-treated_JJ (_( 15_CD '_'' )_) ._SENT (_( C_LS )_) Cell_JJ extract_NN (_( pre-pull-down_NN )_) input_NN levels_NNS of_IN phosphotyrosine_JJ Flt-1_NP and_CC Flt-1_NP ,_, from_IN HUVECs_NP either_CC serum-starved_JJ (_( 0_CD '_'' )_) or_CC starved_VBN and_CC then_RB VEGF-treated_JJ (_( 15_CD '_'' )_) ._SENT (_( D_NP )_) HUVECs_NP were_VBD serum-starved_JJ (_( -_: )_) or_CC VEGF-treated_NP with_IN VEGF_NP (_( 15_CD ng/mL_NNS for_IN 15_CD min_NN )_) (_( +_SYM )_) ._SENT The_DT cell_NN extracts_VBZ were_VBD then_RB immunoprecipitated_JJ using_VBG alpha-KDR/Flk-1_NN (_( N-931_NP )_) ._SENT The_DT immunocomplexes_NNS were_VBD resolved_VBN on_IN a_DT 7_CD %_NN acrylamide_NN SDS-PAGE_NN gel_NN ._SENT Biotinylated_JJ GST_JJ and_CC biotinylated_JJ GST-Src_NP SH3-SH2_NP fusion_NN protein_NN were_VBD used_VBN in_IN Far_NP Western_NP blotting_VBG ._SENT Detection_NN was_VBD performed_VBN using_VBG horseradish_NN peroxidase-conjugated_JJ ExtrAvidin_NP ,_, followed_VBN by_IN enhanced_JJ chemiluminescence_NN detection_NN reagents_NNS ._SENT Immunoprecipitation-Western_JJ blots_NNS for_IN levels_NNS of_IN phosphotyrosine_JJ KDR/Flk-1_NP and_CC KDR/Flk-1_NP of_IN the_DT serum-starved_JJ (_( -_: )_) or_CC VEGF-treated_NP HUVEC_NP (_( +_SYM )_) cell_NN extracts_VBZ were_VBD also_RB performed_VBN in_IN parallel_NN ._SENT In_IN contrast_NN ,_, when_WRB we_PP tested_VBD the_DT same_JJ panel_NN of_IN GST-Src_NP domain_NN fusion_NN proteins_NNS for_IN their_PP$ ability_NN to_TO bind_VB to_TO Flt-1_NP ,_, we_PP did_VBD not_RB observe_VB detectable_JJ binding_NN of_IN Flt-1_NP with_IN the_DT GST-Src_NP domain_NN fusion_NN proteins_NNS ._SENT Levels_NNS of_IN Flt-1_NP were_VBD equivalent_JJ in_IN serum-starved_JJ versus_CC VEGF-treated_JJ cells_NNS ,_, and_CC Flt-1_NP exhibited_VBD tyrosine_NN phosphorylation_NN upon_IN VEGF_NP treatment_NN ._SENT These_DT data_NNS revealed_VBD that_IN Flt-1_NP was_VBD present_JJ and_CC detectable_JJ in_IN lysate_NNS from_IN HUVECs_NP ,_, but_CC was_VBD not_RB able_JJ to_TO interact_VB with_IN the_DT major_JJ protein_NN binding_VBG domains_NNS of_IN Src_NP ._SENT Thus_RB ,_, this_DT data_NN further_RBR supports_VBZ a_DT binding_JJ preference_NN of_IN Src_NP for_IN KDR/Flk-1_NP following_VBG VEGF_NP stimulation_NN ._SENT To_TO further_RBR confirm_VB that_DT VEGF_NP treatment_NN leads_VBZ to_TO an_DT increased_VBN ability_NN of_IN tyrosine_NN phophorylated_JJ KDR/Flk-1_NP to_TO interact_VB with_IN Src_NP SH3-SH2_NP ,_, we_PP performed_VBD Far_NP Western_NP experiments_NNS ._SENT HUVECs_NNS were_VBD either_RB serum-starved_VBN ,_, or_CC starved_VBN and_CC then_RB treated_VBN with_IN VEGF_NP ._SENT Following_VBG immunopreciptiation_NN of_IN cell_NN extracts_VBZ using_VBG alpha-KDR/Flk-1_JJ antibody_NN ,_, biotinylated_JJ GST-Src_NP fusion_NN proteins_NNS were_VBD used_VBN in_IN immunoblotting_NN ._SENT Figure_NN demonstrates_VBZ that_IN KDR/Flk-1_NP exhibits_NNS increased_VBD interaction_NN with_IN Src_NP SH3-SH2_NP domains_NNS after_IN stimulation_NN of_IN HUVECs_NP with_IN VEGF_NP ,_, and_CC after_IN tyrosine_NN phosphorylation_NN of_IN KDR/Flk-1_NP ._SENT Levels_NNS of_IN KDR/Flk-1_NP protein_NN remained_VBD similar_JJ before_IN and_CC after_IN VEGF_NP treatment_NN ,_, and_CC there_EX was_VBD an_DT increase_NN in_IN tyrosine_NN phosphorylation_NN of_IN KDR/Flk-1_NP after_IN VEGF_NP treatment_NN ._SENT Control_NN experiments_NNS indicated_VBD that_IN KDR/Flk-1_NP (_( prior_RB to_TO VEGF_NP treatment_NN and_CC post-VEGF_NN treatment_NN )_) did_VBD not_RB interact_VB with_IN biotinylated-GST_NP alone_RB ._SENT At_IN this_DT time_NN ,_, we_PP do_VBP not_RB know_VB the_DT exact_JJ nature_NN of_IN the_DT binding_JJ interactions_NNS between_IN Src_NP and_CC KDR/Flk-1_NP ._SENT However_RB ,_, we_PP have_VBP observed_VBN that_IN both_CC the_DT Src_NP SH2_NP and_CC SH3_NP domains_NNS appear_VBP to_TO be_VB required_VBN for_IN optimal_JJ binding_NN to_TO KDR/Flk-1_NP (_( data_NN not_RB shown_VBN )_) ._SENT It_PP is_VBZ possible_JJ to_TO speculate_VB that_DT VEGF_NP binding_NN and_CC stimulation_NN of_IN KDR/Flk-1_NP confers_VBZ the_DT proper_JJ conformation_NN to_TO KDR/Flk-1_NP such_JJ that_IN it_PP is_VBZ able_JJ to_TO initially_RB bind_VB the_DT Src_NP SH3_NP domain_NN via_IN the_DT cytoplasmic_JJ KDR/Flk-1_NP proline-rich_JJ regions_NNS and/or_CC KDR/Flk-1_JJ phosphotyrosine_NN sites_NNS ._SENT When_WRB Src_NP is_VBZ able_JJ to_TO bind_VB to_TO this_DT accessible_JJ KDR/Flk-1_NP region_NN ,_, the_DT Src_NP protein_NN itself_PP may_MD be_VB further_RBR opened_VBN up_RP by_IN Src_NP SH2_NP domain_NN binding_VBG to_TO a_DT phosphotyrosine_JJ site_NN on_IN KDR/Flk-1_NP ,_, and_CC Src_NP 's_POS active_JJ site_NN might_MD then_RB be_VB made_VBN fully_RB available_JJ for_IN further_JJR propagation_NN of_IN transducing_VBG cellular_JJ signals_NNS ._SENT Thus_RB in_IN this_DT manner_NN ,_, the_DT binding_JJ interactions_NNS between_IN KDR/Flk-1_NP and_CC Src_NP SH3_NP and_CC Src_NP SH2_NP domain_NN of_IN Src_NP would_MD act_VB to_TO facilitate_VB disruption_NN of_IN intramolecular_JJ ,_, inhibitory_JJ Src_NP SH3/SH2_NP interactions_NNS ._SENT This_DT would_MD ultimately_RB allow_VB Src_NP to_TO open_VB up_RP into_IN an_DT active_JJ conformation_NN ,_, thereby_RB permitting_VBG autophosphorylation_NN on_IN Src_NP Tyr_NP 419_CD ,_, and_CC also_RB upregulation_NN of_IN Src_NP activity_NN by_IN dephosphorylation_NN of_IN negative-regulatory_JJ C-terminal_NP phosphotyrosine_NN 530_CD by_IN phosphatases_NNS ._SENT We_PP are_VBP currently_RB conducting_VBG further_JJR studies_NNS to_TO investigate_VB this_DT model_NN for_IN Src-KDR/Flk-1_JJ interaction_NN ._SENT Although_IN we_PP did_VBD not_RB detect_VB GST-Src_NP unique_JJ domain_NN association_NN with_IN KDR/Flk-1_NP ,_, the_DT presence_NN of_IN the_DT Src_NP unique_JJ domain_NN together_RB with_IN Src_NP SH3-SH2_NP did_VBD increase_VB the_DT extent_NN of_IN the_DT Src-KDR/Flk-1_JJ interaction_NN ._SENT At_IN present_JJ ,_, we_PP do_VBP not_RB know_VB the_DT basis_NN for_IN this_DT enhanced_JJ level_NN of_IN binding_VBG ._SENT However_RB ,_, it_PP is_VBZ notable_JJ that_IN both_DT GST-Unique-SH3-SH2_NP and_CC GST-SH3-SH2_NP Src_NP display_VBP enhanced_JJ association_NN with_IN VEGF-stimulated_JJ ,_, tyrosine-phosphorylated_JJ KDR/Flk-1_NN compared_VBN to_TO unstimulated_JJ KDR/Flk-1_NP ._SENT Our_PP$ findings_NNS suggest_VBP that_IN the_DT Src_NP SH3_NP domain_NN together_RB with_IN the_DT Src_NP SH2_NP domain_NN is_VBZ able_JJ to_TO interact_VB with_IN KDR/Flk-1_NP ._SENT Src_NP family_NN SH3_NP domains_NNS preferentially_RB bind_VBP proline-rich_JJ motifs_NNS with_IN the_DT sequence_NN RPLPXXPX_NP ._SENT The_DT optimal_JJ Src_NP SH2_NP binding_JJ consensus_NN sequence_NN is_VBZ PhipYEEI/Phi_NP (_( where_WRB Phi_NP =_SYM hydrophobic_JJ amino_NN acids_NNS ,_, and_CC E_NP =_SYM glutamate_NN or_CC other_JJ hydrophilic_JJ amino_NN acids_NNS )_) ._SENT Significantly_RB ,_, several_JJ such_JJ potential_JJ Src-binding_NN sites_NNS are_VBP present_JJ on_IN the_DT C-terminal_JJ cytoplasmic_JJ domain_NN of_IN KDR/Flk-1_NP ._SENT A_DT candidate_NN proline-rich_NN ,_, SH3-binding_NP ,_, consensus_NN sequence_NN exists_VBZ in_IN KDR/Flk-1_NP at_IN amino_NN acid_NN region_NN 1192_CD --_: 1198_CD ._SENT Also_RB ,_, several_JJ tyrosine_NN phosphorylation_NN sites_NNS exist_VBP in_IN KDR/Flk-1_NP ._SENT Previously_RB ,_, Cunningham_NP et_FW al._FW have_VBP shown_VBN that_IN tyrosine_NN residues_NNS 801_CD (_( juxtamembranal_NN )_) and_CC 1175_CD (_( C-terminal_NP )_) were_VBD phosphorylated_JJ on_IN KDR/Flk-1_NP ._SENT Tyrosine_NN residues_NNS 951_CD and_CC 996_CD (_( in_IN the_DT kinase_NN insert_NN domain_NN )_) ,_, and_CC 1054_CD and_CC 1059_CD (_( in_IN the_DT C-terminal_JJ kinase_NN domain_NN )_) on_IN KDR/Flk-1_NP have_VBP also_RB been_VBN demonstrated_VBN to_TO be_VB phosphorylated_JJ ._SENT Also_RB ,_, Takahashi_NP and_CC collaborators_NNS have_VBP shown_VBN that_IN in_IN cultured_JJ endothelial_JJ cells_NNS ,_, tyrosine_NN residues_NNS 1175_CD and_CC 1214_CD are_VBP major_JJ phosphorylation_NN sites_NNS ._SENT In_IN a_DT recent_JJ study_NN published_VBN by_IN Meyer_NP et_FW al._FW ,_, VEGF_NP activation_NN of_IN murine_JJ Flk-1_NP was_VBD found_VBN to_TO stimulate_VB Src_NP activity_NN ;_: however_RB ,_, mutational_JJ analysis_NN of_IN tyrosine_NN 1212_CD (_( homologous_JJ tyrosine_NN in_IN murine_JJ Flk-1_NN to_TO tyrosine_NN 1214_CD in_IN human_JJ KDR_NP )_) did_VBD not_RB impair_VB Src_NP activation_NN ,_, providing_VBG an_DT important_JJ clue_NN that_IN tyrosine_NN 1212_CD of_IN murine_JJ Flk-1_NP might_MD not_RB be_VB the_DT major_JJ tyrosine_NN involved_VBN in_IN binding_JJ interactions_NNS with_IN Src_NP ._SENT Coimmunoprecipitation_NP of_IN Fyn_NP and_CC Yes_NP with_IN Flt-1_NP |_SYM The_DT observed_JJ association_NN of_IN Src_NP with_IN KDR/Flk-1_NP upon_IN VEGF_NP stimulation_NN and_CC the_DT lack_NN of_IN detectable_JJ association_NN of_IN Src_NP with_IN Flt-1_NP upon_IN VEGF_NP stimulation_NN prompted_VBD us_PP to_TO examine_VB whether_IN other_JJ Src_NP family_NN kinases_NNS (_( such_JJ as_IN Fyn_NP and_CC Yes_NP )_) might_MD be_VB recruited_VBN in_IN a_DT similar_JJ or_CC different_JJ manner_NN upon_IN VEGF_NP stimulation_NN ._SENT HUVECs_NNS were_VBD serum-starved_VBN and_CC treated_VBN with_IN VEGF_NP 15_CD ng/mL_NNS for_IN 15_CD min_NN ,_, and_CC the_DT cell_NN extracts_VBZ were_VBD immunoprecipitated_VBN with_IN either_DT alpha-Fyn_NN or_CC alpha-Yes_NNS ,_, and_CC Western_NP blotted_VBD for_IN Flt-1_NP ._SENT Unlike_IN Src_NP ,_, Fyn_NP and_CC Yes_NP were_VBD found_VBN to_TO preferentially_RB associate_VB with_IN Flt-1_NP ,_, following_VBG VEGF_NP treatment_NN (_( Fig._NN and_CC )_) ._SENT Concurrently_RB ,_, Flt-1_JJ immunoprecipitation_NN and_CC Flt-1_JJ tyrosine_NN phosphorylation_NN was_VBD also_RB detectable_JJ ._SENT In_IN contrast_NN ,_, we_PP did_VBD not_RB observe_VB any_DT detectable_JJ amounts_NNS of_IN Fyn_NP or_CC Yes_NP coimmunoprecipitating_VBG with_IN KDR/Flk-1_NP upon_IN VEGF_NP treatment_NN (_( Fig._NN and_CC )_) ._SENT Control_NN experiments_NNS indicate_VBP that_IN indeed_RB ,_, despite_IN our_PP$ observation_NN that_IN Fyn_NP and_CC Yes_NP did_VBD not_RB seem_VB to_TO coimmunoprecipitate_VB with_IN KDR/Flk-1_NP ,_, KDR/Flk-1_NP immunoprecipitation_NP and_CC KDR/Flk-1_NP tyrosine_NN phosphorylation_NN was_VBD still_RB detectable_JJ ._SENT Figure_NP 4_CD |_SYM Coimmunoprecipitation_NN of_IN Fyn_NP with_IN Flt-1_NP ,_, and_CC Yes_NP with_IN Flt-1_NP Coimmunoprecipitation_NP of_IN Fyn_NP with_IN Flt-1_NP ,_, and_CC Yes_NP with_IN Flt-1.HUVECs_NP were_VBD serum-starved_JJ (_( -_: )_) ,_, or_CC starved_VBN and_CC then_RB treated_VBN with_IN VEGF_NP (_( 15_CD ng/mL_NNS for_IN 15_CD min_NN )_) (_( +_SYM )_) ._SENT The_DT cell_NN extracts_VBZ were_VBD then_RB subjected_VBN to_TO immunoprecipitation-Western_VB blotting_VBG experiments_NNS ._SENT (_( A_NP )_) Cell_NP extracts_VBZ from_IN the_DT indicated_JJ treatment_NN conditions_NNS were_VBD immunoprecipitated_JJ using_VBG alpha-Fyn_NN ,_, and_CC immunoblotted_JJ using_VBG alpha-Flt-1_NN (_( H-225_NP )_) ,_, alpha-KDR/Flk-1_JJ (_( A-3_NP )_) ,_, or_CC alpha-Fyn_NP ._SENT (_( B_NP )_) Cell_NP extracts_VBZ from_IN the_DT indicated_JJ treatment_NN conditions_NNS were_VBD immunoprecipitated_VBN using_VBG alpha-Yes_NNS ,_, and_CC immunoblotted_JJ using_VBG alpha-Flt-1_NN (_( H-225_NP )_) ,_, alpha-KDR/Flk-1_JJ (_( A-3_NP )_) ,_, or_CC alpha-Yes_NNS ._SENT (_( C_NP )_) Cell_NP extracts_VBZ from_IN the_DT indicated_JJ treatment_NN conditions_NNS were_VBD immunoprecipitated_JJ using_VBG alpha-Flt-1_NN (_( H-225_NP )_) ,_, and_CC immunoblotted_JJ using_VBG alpha-phosphotyrosine_NN (_( 4G10_JJ )_) or_CC alpha-Flt-1_JJ (_( H-225_NP )_) ._SENT (_( D_NP )_) Cell_NP extracts_VBZ from_IN the_DT indicated_JJ treatment_NN conditions_NNS were_VBD immunoprecipitated_JJ using_VBG alpha-KDR/Flk-1_NN (_( N-931_NP )_) ,_, and_CC immunoblotted_JJ using_VBG alpha-phosphotyrosine_NN (_( 4G10_JJ )_) or_CC alpha-KDR/Flk-1_JJ (_( A-3_NP )_) ._SENT These_DT results_NNS are_VBP consistent_JJ with_IN previous_JJ findings_NNS by_IN Waltenberger_NP and_CC collaborators_NNS who_WP demonstrated_VBD that_IN Fyn_NP and_CC Yes_NP exhibited_VBD increased_VBN levels_NNS of_IN tyrosine_NN phosphorylation_NN upon_IN VEGF_NP stimulation_NN (_( using_VBG stably_RB transfected_JJ ,_, VEGFR-overexpressing_JJ porcine_JJ aortic_JJ endothelial_JJ cell_NN lines_NNS )_) ._SENT Interestingly_RB ,_, they_PP observed_VBD that_IN ,_, in_IN porcine_JJ aortic_JJ endothelial_JJ cell_NN lines_NNS stably_RB overexpressing_VBG Flt-1_NP ,_, increases_NNS in_IN Fyn_NP and_CC Yes_NP tyrosine_NN phosphorylation_NN occurred_VBD in_IN the_DT VEGF-treated_JJ cells_NNS (_( 2.4_CD fold_NN and_CC 2.1_CD fold_NN ,_, respectively_RB )_) ._SENT Also_RB ,_, they_PP noted_VBD that_IN increases_NNS in_IN Fyn_NP and_CC Yes_NP tyrosine_NN phosphorylation_NN did_VBD not_RB occur_VB upon_IN VEGF_NP stimulation_NN in_IN the_DT KDR/Flk-1-overexpressing_NP cell_NN line_NN ._SENT However_RB ,_, they_PP did_VBD not_RB examine_VB Src_NP in_IN their_PP$ study_NN ._SENT Thus_RB ,_, taken_VBN together_RB ,_, our_PP$ data_NNS and_CC this_DT previous_JJ report_NN indicate_VBP that_IN Src_NP preferentially_RB interacts_VBZ with_IN KDR/Flk-1_NP ,_, whereas_IN Fyn_NP and_CC Yes_NP preferentially_RB interact_VBP with_IN Flt-1_NP ,_, following_VBG VEGF_NP stimulation_NN ._SENT A_DT bit_NN unexpectedly_RB ,_, through_IN the_DT course_NN of_IN our_PP$ experiments_NNS we_PP have_VBP found_VBN that_IN our_PP$ detection_NN of_IN Flt-1_NP in_IN the_DT HUVECs_NP used_VBD here_RB is_VBZ somewhat_RB better_RBR than_IN has_VBZ been_VBN reported_VBN in_IN many_JJ previous_JJ publications_NNS (_( Fig._NN ,_, )_) ._SENT We_PP note_VBP that_IN the_DT HUVECs_NP utilized_VBD in_IN our_PP$ study_NN are_VBP primary_JJ and_CC early_JJ passage_NN cells_NNS ,_, kindly_RB provided_VBN by_IN Dr._NP K._NP Patel_NP ._SENT Also_RB ,_, they_PP are_VBP seeded_VBN from_IN harvest_NN initially_RB in_IN human_JJ serum_NN rather_RB than_IN fetal_JJ calf_NN serum_NN ._SENT Therefore_RB ,_, it_PP is_VBZ possible_JJ that_IN they_PP might_MD retain_VB many_JJ endothelial_JJ specific_JJ markers_NNS (_( such_JJ as_IN Flt-1_NP )_) at_IN higher_JJR levels_NNS than_IN might_MD be_VB present_JJ in_IN HUVECs_NP utilized_VBD under_IN different_JJ conditions_NNS ._SENT It_PP is_VBZ also_RB possible_JJ that_IN ,_, to_TO some_DT extent_NN ,_, the_DT differences_NNS in_IN VEGF-induced_NP signaling_VBG between_IN Src_NP compared_VBN to_TO Fyn_NP and_CC Yes_NP may_MD be_VB due_JJ to_TO the_DT differential_JJ localization_NN of_IN the_DT Src_NP family_NN members_NNS ._SENT For_IN example_NN ,_, perhaps_RB Flt-l-Fyn/Yes_NP complexes_NNS localize_VBP to_TO a_DT greater_JJR extent_NN to_TO caveolae_NNS fractions_NNS of_IN cells_NNS ,_, whereas_IN KDR/Flk-1-Src_NP complexes_NNS might_MD be_VB more_RBR generally_RB distributed_VBN in_IN the_DT plasma_NN membrane_NN ._SENT This_DT may_MD allow_VB for_IN appropriate_JJ fine-tuning_NN of_IN differential_NN signaling_VBG ._SENT Notably_RB ,_, there_EX is_VBZ strong_JJ evidence_NN supporting_VBG a_DT model_NN that_IN dually_RB acylated_JJ (_( e.g._FW ,_, myristylated_JJ and_CC palmitylated_JJ )_) Src_NP family_NN kinases_NNS ,_, which_WDT include_VBP all_DT Src_NP family_NN kinases_NNS with_IN the_DT exceptions_NNS of_IN Src_NP and_CC Blk_NP ,_, have_VBP the_DT potential_NN to_TO be_VB localized_VBN to_TO specific_JJ plasma_NN membrane_NN subdomains_NNS (_( such_JJ as_IN caveolae_NNS )_) ._SENT On_IN the_DT other_JJ hand_NN ,_, Src_NP itself_PP ,_, which_WDT is_VBZ only_RB myristylated_JJ ,_, has_VBZ been_VBN reported_VBN to_TO not_RB localize_VB in_IN these_DT microcompartments_NNS ._SENT Undoubtedly_RB ,_, post-translational_JJ modifications_NNS of_IN proteins_NNS would_MD play_VB a_DT very_RB large_JJ role_NN in_IN regulating_VBG spatial_JJ and_CC temporal_JJ specificity_NN in_IN signal_NN transduction_NN in_IN these_DT distinct_JJ microcompartments_NNS ._SENT Our_PP$ experiments_NNS have_VBP revealed_VBN several_JJ important_JJ features_NNS of_IN c-Src_NP involvement_NN in_IN the_DT early_JJ steps_NNS of_IN VEGF-mediated_NP signaling_VBG in_IN HUVECs_NP ._SENT Of_IN primary_JJ importance_NN was_VBD the_DT finding_NN that_IN Src_NP became_VBD associated_VBN preferentially_RB with_IN KDR/Flk-1_NP ,_, rather_RB than_IN with_IN Flt-1_NP ,_, upon_IN VEGF_NP stimulation_NN and_CC VEGFR_NP activation_NN ._SENT This_DT binding_NN of_IN Src_NP to_TO KDR/Flk-1_NP and_CC subsequent_JJ activation_NN of_IN Src_NP was_VBD enhanced_VBN by_IN tyrosine_NN phosphorylation_NN of_IN KDR/Flk-1_NP ._SENT We_PP also_RB observed_VBD that_IN ,_, although_IN Src_NP binds_VBZ preferentially_RB to_TO KDR/Flk-1_NP ,_, two_CD other_JJ Src_NP family_NN members_NNS ,_, Fyn_NP and_CC Yes_NP ,_, bind_NN preferentially_RB to_TO the_DT Flt-1_JJ receptor_NN upon_IN stimulation_NN of_IN HUVECs_NP with_IN VEGF_NP ._SENT These_DT results_NNS are_VBP consistent_JJ with_IN previous_JJ results_NNS that_WDT indicate_VBP that_IN Fyn_NP and_CC Yes_NP exhibited_VBD increased_VBN levels_NNS of_IN phosphorylation_NN upon_IN VEGF_NP stimulation_NN in_IN porcine_JJ aortic_JJ endothelial_JJ cells_NNS stably_RB overexpressing_VBG Flt-1_NP ._SENT This_DT difference_NN in_IN specificities_NNS may_MD be_VB a_DT key_JJ mode_NN of_IN fine-tuning_NN downstream_IN signals_NNS capitalized_VBN on_IN by_IN endothelial_JJ cells_NNS ._SENT In_IN this_DT manner_NN ,_, it_PP is_VBZ possible_JJ that_IN endothelial_JJ cells_NNS could_MD appropriately_RB gear_VB their_PP$ responses_NNS towards_IN induction_NN of_IN vascular_JJ permeability_NN and_CC mitogenicity_NN through_IN signals_NNS transmitted_VBN by_IN KDR/Flk-1_NP ,_, or_CC vascular_JJ remodeling_NN and_CC revascularization_NN through_IN signals_NNS transmitted_VBN by_IN Flt-1_NP ,_, to_TO meet_VB the_DT specific_JJ need_NN of_IN a_DT tissue_NN depending_VBG on_IN local_JJ requirements_NNS ._SENT Materials_NNS |_SYM Human_JJ recombinant_JJ VEGF-A165_NN and_CC enolase_NN were_VBD purchased_VBN from_IN Sigma_NP ._SENT Polyclonal_NP alpha-KDR/Flk-1_NP (_( N-931_NP )_) raised_VBD against_IN amino_NN acids_NNS 931_CD --_: 997_CD of_IN Flk-1_NP ,_, monoclonal_NN alpha-KDR/Flk-1_NN (_( A-3_NP )_) raised_VBD against_IN amino_NN acids_NNS 1158_CD --_: 1345_CD of_IN the_DT carboxyl_NN terminus_NN of_IN Flk-1_NP ,_, polyclonal_JJ alpha-Flt-1_NN (_( H-225_NP )_) raised_VBD against_IN amino_NN acids_NNS 23_CD --_: 247_CD mapping_NN within_IN the_DT extracellular_JJ domain_NN of_IN Flt-1_NP of_IN human_JJ origin_NN ,_, alpha-Fyn_NP (_( FYN3_NP )_) ,_, and_CC alpha-Yes_NNS (_( 3_CD )_) were_VBD purchased_VBN from_IN Santa_NP Cruz_NP Biotechnology_NP ._SENT alpha-Src_NN phosphotyrosine_NN 419_CD antibody_NN was_VBD from_IN Cell_NP Signaling_NP ._SENT alpha-Src_NN monoclonal_NN antibodies_NNS were_VBD purified_VBN from_IN hybridomas_NNS obtained_VBN from_IN Quality_NP Biotech_NP (_( alpha-Src_NN 2_CD --_: 17_LS )_) or_CC from_IN hybridomas_NNS provided_VBN by_IN Dr._NP Joan_NP Brugge_NP (_( alpha-Src_NP 327_CD )_) ._SENT alpha-phosphotyrosine_NP (_( 4G10_JJ )_) was_VBD provided_VBN by_IN Dr._NP Stephen_NP Robbins_NP ._SENT Cell_NN culture_NN |_SYM Human_JJ umbilical_JJ vein_NN endothelial_JJ cells_NNS (_( HUVECs_NP )_) were_VBD provided_VBN by_IN Dr._NP Kamala_NP Patel_NP (_( University_NP of_IN Calgary_NP )_) ._SENT These_DT cells_NNS were_VBD isolated_VBN from_IN human_JJ umbilical_JJ cord_NN veins_NNS by_IN collagenase_NN treatment_NN as_RB described_VBD previously_RB ._SENT HUVECs_NNS were_VBD maintained_VBN in_IN M199_NP medium_NN (_( Gibco_NP )_) containing_VBG 10_CD %_NN fetal_JJ bovine_JJ serum_NN ,_, 2.2_CD mg/mL_NN sodium_NN bicarbonate_NN ,_, 2.4_CD mug/mL_NN thymidine_NN ,_, 10_CD units/mL_NN heparin_NN ,_, 2_CD mM_NP glutamine_NN ,_, and_CC antibiotics_NNS (_( 100_CD units/mL_NN penicillin_NN ,_, 100_CD mug/mL_NN streptomycin_NN )_) at_IN 37C_JJ in_IN 5_CD %_NN CO2_NN ._SENT Immunoprecipitations_NNS |_SYM HUVECs_NP were_VBD serum-starved_VBN for_IN 24_CD h_NN and_CC then_RB treated_VBN with_IN VEGF_NP (_( 15_CD ng/mL_NNS )_) for_IN 0_CD ,_, 15_CD ,_, 30_CD ,_, 60_CD ,_, or_CC 120_CD min_NN ._SENT Cells_NNS were_VBD washed_VBN two_CD times_NNS with_IN PBS_NP on_IN ice_NN ._SENT The_DT cells_NNS were_VBD then_RB scraped_VBN in_IN 1_CD mL_NN of_IN 1_CD %_NN NP-40_JJ lysis_NN buffer_NN (_( 150_CD mM_NP NaCl_NP ,_, 50_CD mM_NP Tris_NP pH_NN 7.5_CD ,_, 1_CD %_NN Nonidet_NP P-40_NP ,_, 2_CD mM_NP EDTA_NP ,_, 50_CD mug/mL_NN leupeptin_NN ,_, 10_CD mug/mL_NN aprotinin_NN ,_, 200_CD muM_NN sodium_NN orthovanadate_NNS ,_, 4_CD mg/mL_NN p-nitrophenyl_NN phosphate_NN )_) ._SENT The_DT scraped_VBN cells_NNS were_VBD briefly_RB vortexed_VBN ,_, and_CC then_RB incubated_VBN on_IN ice_NN for_IN 10_CD min_NN ._SENT Cell_NN extracts_VBZ were_VBD then_RB clarified_VBN by_IN centrifugation_NN at_IN 4C_JJ ,_, 10_CD 000_CD x_SYM g_NN for_IN 10_CD min_NN ._SENT Cell_NN extract_NN samples_NNS for_IN immunoprecipitation_NN were_VBD precleared_VBN using_VBG 10_CD muL_NN packed_VBN Protein_NP A/G_NP (_( 1:1_CD )_) and_CC mixing_VBG on_IN a_DT rotator_NN at_IN 4C_JJ 30_CD min_NN ._SENT Centrifugation_NN at_IN 14000_CD rpm_NN in_IN a_DT cold_JJ microcentrifuge_NN for_IN 2_CD minutes_NNS was_VBD then_RB conducted_VBN and_CC the_DT precleared_JJ cell_NN extract_NN supernatant_JJ was_VBD collected_VBN ._SENT Immunoprecipitations_NNS were_VBD performed_VBN using_VBG 15_CD mug_NN alpha-Src_NN 2_CD --_: 17_CD per_IN 1_CD mg_NN cell_NN extract_NN ,_, or_CC 3_CD mug_NN alpha-KDR_NN or_CC 3_CD mug_NN alpha-Flt-1_JJ per_IN 1_CD mg_NN extract_NN ,_, and_CC 15_CD muL_NN packed_VBN Protein_NP G_NP agarose_NN ._SENT The_DT immunoprecipitations_NNS were_VBD mixed_VBN on_IN a_DT rotator_NN at_IN 4C_JJ for_IN 2_CD h._NN The_DT immune_JJ complexes_NNS were_VBD washed_VBN 3_CD times_NNS with_IN 1_CD %_NN NP-40_JJ lysis_NN buffer_NN ._SENT Samples_NNS for_IN Westerns_NNS were_VBD boiled_VBN for_IN 5_CD min_NN in_IN 1X_NP Laemmli_NP 's_POS sample_NN buffer_NN ,_, and_CC resolved_VBN on_IN 7_CD %_NN or_CC 10_CD %_NN acrylamide_NN SDS-PAGE_NN gels_NNS ._SENT c-Src_NP Kinase_NP Activity_NP Assays_NPS |_SYM HUVECs_NP were_VBD either_RB serum-starved_VBN for_IN 24_CD h_NN ,_, or_CC starved_VBN and_CC then_RB treated_VBN with_IN VEGF_NP (_( 15_CD ng/mL_NNS )_) ._SENT Cell_NN lysates_NNS of_IN these_DT samples_NNS were_VBD then_RB immunoprecipitated_VBN using_VBG alpha-KDR/Flk-1_JJ ,_, alpha-Flt-1_JJ ,_, or_CC rabbit_NN nonimmune_NN IgG_NP (_( rabbit_NN IgG_NP )_) ._SENT The_DT immune_JJ complexes_NNS were_VBD washed_VBN 3_CD times_NNS with_IN 0.8_CD mL_NN of_IN 1_CD %_NN NP-40_JJ lysis_NN buffer_NN ,_, and_CC once_RB with_IN 0.8_CD mL_NN Src_NP kinase_NN buffer_NN (_( 20_CD mM_NP Tris_NP pH_NN 7.2_CD ,_, 5.0_CD mM_NP MnCl2_NP )_) and_CC put_VB on_IN ice_NN for_IN 5_CD min_NN ._SENT The_DT pellets_NNS were_VBD then_RB centrifuged_VBN and_CC the_DT supernatant_JJ buffer_NN aspirated_VBD ._SENT Each_DT kinase_NN reaction_NN was_VBD started_VBN by_IN the_DT addition_NN of_IN 33_CD muL_NN Src_NP kinase_NN reaction_NN hot_JJ mix_NN (_( consisting_VBG of_IN 30_CD muL_NN of_IN Src_NP kinase_NN buffer_NN ,_, 2_CD muL_NN of_IN 2.5_CD mug/mL_NN enolase_NN ,_, and_CC 1_CD muL_NN (_( 10_CD muCi_NNS )_) of_IN [_SYM gamma-32P]ATP_NN (_( >3000_NP Ci/mmol_NP )_) ._SENT The_DT reaction_NN was_VBD incubated_VBN at_IN 30C_JJ for_IN 20_CD min_NN ._SENT The_DT reactions_NNS were_VBD then_RB stopped_VBN by_IN the_DT addition_NN of_IN 33_CD muL_NN of_IN 2X_NP Laemmli_NP 's_POS sample_NN buffer_NN and_CC boiled_VBD for_IN 5_CD min_NN ._SENT Samples_NNS were_VBD resolved_VBN on_IN 10_CD %_NN SDS-PAGE_NN gels_NNS ._SENT The_DT gels_NNS were_VBD treated_VBN with_IN 1_CD M_NP KOH_NP at_IN 55C_NP for_IN 1_CD h_NN after_IN electrophoresis_NN to_TO remove_VB background_NN due_JJ to_TO serine_NN phosphorylation_NN ._SENT The_DT gels_NNS were_VBD dried_VBN and_CC exposed_VBN to_TO autoradiographic_NN film_NN ._SENT Band_NN intensities_NNS were_VBD quantified_VBN by_IN densitometry_NN of_IN the_DT autoradiogram_NN ._SENT GST-Src_NP domain_NN fusion_NN constructs_NNS and_CC expression_NN |_SYM The_DT required_JJ Src_NP domain_NN cDNA_NN fragments_NNS were_VBD generated_VBN by_IN restriction_NN digestion_NN from_IN pBA3CS_NNS ,_, which_WDT contained_VBD full-length_JJ wild_JJ type_NN human_JJ c-Src_NP cDNA_NN ._SENT pG-U_NP contains_VBZ the_DT human_JJ c-Src_NP unique_JJ domain_NN (_( nt_RB 1_CD --_: 170_CD ,_, aa_NN 1_CD --_: 57_LS )_) obtained_VBN by_IN restriction_NN digestion_NN of_IN pBA3CS-human_NP c-Src_NP using_VBG NcoI_NP and_CC NotI_NP ._SENT pG-U32_NN contains_VBZ human_JJ c-Src_NN unique_JJ ,_, SH3_NP ,_, and_CC SH2_NP domains_NNS (_( nt_RB 1_CD --_: 775_CD ,_, aa_NN 1_CD --_: 258_LS )_) obtained_VBN by_IN restriction_NN digestion_NN using_VBG NcoI_NP and_CC EcoNI_NP ._SENT pG-32_NN contains_VBZ human_JJ c-Src_NP SH3_NP and_CC SH2_NP domains_NNS (_( nt_RB 170_CD --_: 775_CD ,_, aa_NN 57_CD --_: 258_LS )_) obtained_VBN by_IN restriction_NN digestion_NN using_VBG NotI_NP and_CC EcoNI_NP ._SENT The_DT Src_NP cDNA_NN fragments_NNS above_RB were_VBD treated_VBN with_IN Klenow_NP to_TO blunt_VB their_PP$ ends_NNS before_IN ligation_NN in_IN frame_NN into_IN pGEX-2T_NN ._SENT Each_DT pGEX-Src_NN fusion-containing_VBG E._NP coli_NNS BL21_NP clone_NN was_VBD cultured_VBN in_IN 10_CD mL_NN 2x_JJ YTA_NP broth_NN (_( 16_CD g/L_NN tryptone_NN ,_, 10_CD g/L_NN yeast_NN extract_NN ,_, 5_CD g/L_NN NaCl_NP ,_, 100_CD mug/mL_NN ampicillin_NN ,_, pH_NN 7.0_CD )_) overnight_JJ at_IN 30C_JJ ,_, shaking_VBG at_IN 250_CD rpm_NN ._SENT The_DT starter_JJ culture_NN was_VBD diluted_VBN 1:100_CD into_IN 400_CD mL_NN of_IN fresh_JJ 2xYTA_JJ broth_NN and_CC grown_VBN at_IN 30C_JJ ,_, shaking_VBG at_IN 250_CD rpm_NN ,_, until_IN A600_NP reached_VBD 0.5_CD --_: 2_LS ._SENT The_DT culture_NN was_VBD then_RB induced_VBN by_IN the_DT addition_NN of_IN isopropyl-beta-D-thiogalactoside_NN to_TO a_DT final_JJ concentration_NN of_IN 0.2_CD mM_NNS for_IN 3_CD h_NN at_IN 30C_JJ ,_, shaking_VBG at_IN 250_CD rpm_NN ._SENT GST-Src_NP fusion_NN protein_NN harvesting_NN and_CC purification_NN was_VBD carried_VBN out_IN following_VBG pGEX_JJ vector_NN supplier_NN 's_POS instructions_NNS (_( Amersham_NP Pharmacia_NP Biotech_NP )_) ._SENT GST-Src_NP domain_NN fusion_NN protein_NN pull-downs_NNS of_IN KDR/Flk-1_NP |_SYM HUVECs_NP were_VBD starved_VBN in_IN serum-free_JJ medium_NN for_IN 24_CD h_NN and_CC then_RB treated_VBN with_IN VEGF_NP (_( 15_CD ng/mL_NNS )_) for_IN 0_CD or_CC 15_CD min_NN ._SENT Equimolar_JJ amounts_NNS of_IN the_DT various_JJ GST-Src_NP domain_NN fusion_NN proteins_NNS (_( 500_CD pmol_NN )_) bound_VBN to_TO Glutathione-agarose_NP beads_NNS were_VBD used_VBN in_IN pull-down_JJ incubations_NNS (_( at_IN 4C_JJ for_IN 3_CD hours_NNS )_) with_IN equal_JJ amounts_NNS of_IN cell_NN extracts_VBZ (_( 500_CD mug_NN )_) ._SENT The_DT fusion_NN protein_NN complexes_NNS were_VBD pelleted_VBN by_IN centrifugation_NN and_CC washed_VBD three_CD times_NNS with_IN lysis_NN buffer_NN ._SENT The_DT washed_JJ fusion_NN protein_NN pellets_NNS were_VBD boiled_VBN in_IN 1X_NP Laemmli_NP 's_POS sample_NN buffer_NN ,_, resolved_VBN on_IN a_DT 7_CD %_NN acrylamide_NN SDS-PAGE_NP gel_NN ,_, and_CC transferred_VBN to_TO nitrocellulose_NN ._SENT Afterward_RB ,_, immunoblotting_NN was_VBD performed_VBN and_CC results_NNS were_VBD developed_VBN by_IN using_VBG enhanced_JJ chemiluminescence_NN (_( Amersham_NP )_) ._SENT Far_RB western_JJ blotting_VBG |_SYM GST-Src_NP domain_NN fusion_NN proteins_NNS were_VBD biotinylated_JJ at_IN room_NN temperature_NN for_IN 3_CD h_NN with_IN biotinamidocaproate-N-hydroxysuccinimide_NN ester_NN (_( 100_CD mug/mL_NN ,_, Sigma_NP )_) at_IN a_DT fusion_NN protein_NN concentration_NN of_IN 2_CD mg/mL_NN in_IN 0.1_CD M_NP sodium_NN borate_NN ,_, pH_NN 8.8_CD ._SENT Biotinylated_JJ protein_NN was_VBD purified_VBN extensively_RB by_IN washes_VBZ using_VBG PBS_NP ,_, pH_NN 7.5_CD ,_, 2_CD mM_NP dithiothreitol_NN through_IN a_DT MICROSEP_JJ microconcentrator_NN (_( Filtron_NP Technology_NP ,_, according_VBG to_TO manufacturer_NN 's_POS instructions_NN )_) ._SENT The_DT final_JJ biotinylated_JJ protein_NN products_NNS were_VBD used_VBN at_IN concentrations_NNS of_IN 2_CD mug/mL_NN in_IN PBS_NP ,_, 1_CD mM_NP dithiothreitol_NN ,_, in_IN Far_NP Western_NP blotting_VBG of_IN nitrocellulose_NN membranes_NNS ._SENT Biotinylated_JJ probes_NNS were_VBD detected_VBN with_IN horseradish_NN peroxidase-conjugated_VBN ExtrAvidin_NP (_( Sigma_NP )_) at_IN 1:2000_CD dilution_NN in_IN PBS_NP ,_, 3_CD %_NN BSA_NP ,_, 0.05_CD %_NN Tween-20_NP ._SENT Results_NNS were_VBD developed_VBN by_IN reaction_NN using_VBG enhanced_JJ chemiluminescence_NN (_( Amersham_NP )_) ._SENT Flt-1_JJ ,_, Fms-like_JJ tyrosine_NN kinase-1_NN ;_: G32_NP ,_, GST-Src_NP SH3_NP Src_NP SH2_NP domain_NN fusion_NN protein_NN ;_: GST_NP ,_, glutathione-S-transferase_NN ;_: GU_NP ,_, GST-Src_NP unique_JJ domain_NN fusion_NN protein_NN ;_: HUVEC_NP ,_, human_JJ umbilical_JJ vein_NN endothelial_JJ cell_NN ;_: KDR/Flk-1_NP ,_, kinase_NN insert_NN domain-containing_VBG receptor/fetal_JJ liver_NN kinase-1_NN ;_: pG_NN ,_, pGEX_NN vector_NN ;_: VEGF_NP ,_, vascular_JJ endothelial_JJ growth_NN factor_NN ._SENT MC_NP conducted_VBD the_DT biochemical_JJ and_CC molecular_JJ experiments_NNS and_CC wrote_VBD the_DT first_JJ draft_NN of_IN the_DT manuscript_NN ._SENT JW_NNS participated_VBD in_IN making_VBG the_DT GST-Src_NP domain_NN fusion_NN constructs_NNS ._SENT DF_NP conceived_VBD of_IN the_DT study_NN ,_, participated_VBN in_IN its_PP$ design_NN ,_, supervised_VBD the_DT work_NN of_IN MC_NP and_CC JW_NP ,_, and_CC oversaw_VBD subsequen_NNS 